Best for skin and anti-aging
These four peptides represent the most discussed compounds in skin and anti-aging contexts. Each is listed with its evidence level, regulatory status, and a link to its full compound page. This curation separates cosmetic skincare evidence from systemic anti-aging claims and does not provide dosing, treatment, or purchasing guidance.
GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the most extensively researched copper peptide for skin repair. It appears across wound healing, collagen synthesis, and cosmetic skincare literature, making it the anchor compound for any skin peptide curation.
Evidence level: Peer reviewed
Regulatory status: OTC cosmetic ingredient in the US. No FDA drug approval. The FDA warning letter on peptide compounding applies to GHK-Cu products marketed beyond cosmetic use. Systemic or injectable claims fall outside approved cosmetic use.
Peer-reviewed reviews describe GHK-Cu as a bioactive copper peptide with wound healing and skin repair properties based on in vitro and cosmetic research. The primary review (Pickart et al., 2012) is comprehensive but originates from the peptide's discoverer. Evidence is scoped to cosmetic and preclinical contexts — no large-scale human trials for systemic anti-aging use exist.
Argireline (Acetyl Hexapeptide-8)
Argireline (Acetyl Hexapeptide-8) is a synthetic hexapeptide fragment of SNAP-25 — one of the targets of botulinum toxin. Marketed as 'botox in a jar,' it is the most recognizable topical wrinkle-reduction peptide in consumer skincare and one of the few with a randomized controlled trial.
Evidence level: Peer reviewed
Regulatory status: OTC cosmetic ingredient in the US with no FDA drug approval. Widely marketed as a topical anti-wrinkle ingredient. Not regulated as a drug.
A randomized, placebo-controlled study (n=60) showed that topical 10% acetyl hexapeptide-8 applied twice daily for 4 weeks reduced peri-orbital wrinkle depth (Wang et al., Am J Clin Dermatol, 2013). The SNARE inhibition mechanism is proposed based on the peptide's relationship to SNAP-25 but clinical evidence for this mechanism in human skin is limited. Do not equate topical argireline to botulinum toxin injections, which have substantially stronger evidence.
Matrixyl (Palmitoyl Pentapeptide-4)
Matrixyl (Palmitoyl Pentapeptide-4, formerly Palmitoyl Pentapeptide-3) is a matrikine peptide (Pal-KTTKS) and one of the most researched cosmetic peptides for collagen stimulation and wrinkle reduction. Originally launched by Sederma SAS in 2000, it has a 12-week double-blind placebo-controlled clinical trial supporting its use.
Evidence level: Peer reviewed
Regulatory status: OTC cosmetic ingredient with no FDA drug approval. Widely available in over-the-counter skincare products marketed with collagen stimulation claims.
A 12-week double-blind, placebo-controlled, split-face RCT (n=93, Caucasian females aged 35-55) showed that topical 3 ppm pal-KTTKS provided significant improvement in fine lines and wrinkles vs. placebo (Robinson et al., Int J Cosmet Sci, 2005). In vitro studies demonstrate collagen neosynthesis, and permeation studies confirm the palmitoyl chain improves skin penetration. Evidence supports modest improvement — do not overstate as equivalent to prescription retinoids or procedures.
Epitalon
Epitalon (Ala-Glu-Asp-Gly) is included as the telomere research entry — the most discussed peptide in longevity and anti-aging biology contexts. It represents the boundary between cosmetic skin peptides and systemic anti-aging claims, and requires the most conservative editorial framing.
Evidence level: Peer reviewed (single-group preclinical)
Regulatory status: Research peptide under FDA regulatory review. Scheduled for FDA Pharmacy Compounding Advisory Committee discussion in July 2026. Listed on the FDA bulk drug substances risk list for compounding. Not approved for any indication.
Studies from a single Russian research group (Khavinson et al.) report that Epitalon increases telomerase activity in human cells. This telomerase claim lacks independent Western replication. Online longevity content promotes Epitalon as an anti-aging peptide despite the absence of large-scale human clinical trials. Reviews note that geroprotective claims rest on preclinical data from limited research groups.
This page is an editorial curation, not a purchasing recommendation or treatment protocol. Cosmetic peptides (GHK-Cu, Argireline, Matrixyl) are regulated as OTC cosmetic ingredients in the US, not drugs. Epitalon is a research peptide under FDA regulatory review. Evidence levels vary significantly — from controlled clinical trials for topical cosmetics to preclinical-only data for systemic anti-aging claims.
Source records are stored in the repo and linked from this page.
Pickart et al. (2012) comprehensive review of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) as a bioactive peptide with wound healing, skin repair, and anti-inflammatory properties, citing both in vitro and clinical cosmetic evidence.
Reviews and studies of GHK-Cu in wound healing contexts, describing its modulation of multiple gene pathways related to tissue repair, collagen synthesis, and anti-inflammatory responses. Primarily preclinical and cosmetic research.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
Studies by Khavinson and colleagues reporting that Epitalon (Ala-Glu-Asp-Gly) increases telomerase activity in human somatic cells. Research is primarily from a single Russian research group and lacks independent Western replication.
Reviews of Epitalon and related peptides in the context of aging biology, noting that telomerase and longevity claims rest on preclinical data from limited research groups without large-scale human clinical trials.
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.